Payton Nyquvest, the chief executive of Numinus Wellness Inc. (TSE: NUMI) (OTCMKTS: NUMIF) a mental health and wellness company merging the practices of administering psychedelic medicine with holistic integrated psychotherapy has discussed two upcoming clinical trials with MDMA and psilocybin.
According to the CEO, the company’s phase 1 proprietary psilocybin extract dubbed NBI0-01 will be used in one of the clinical trials. NBI0-01 is naturally extracted and these clinical trials will come at a time when psychedelic legalization laws are taking shape in some states like Oregon.
“I mentioned Oregon, which if you if you look at those regulations, legal, natural psilocybin, they’ve clearly spelled out that they’re not looking for synthetic. Not only they’re not looking for, but they’re not going to be approving synthetic psilocybin as it is right now. So there’s a really a very, very strong interest in natural psilocybin,” said the CEO.
In the beginning of the year Numins announced that its research facility, Numinus Bioscience, had been included on Health Canada’s list of federally licensed psilocybin producers. The CEO goes further and points out a brief difference between natural and synthetic psilocybin.
“Natural psilocybin or psilocybin is something that occurs within psilocybin-containing fungi. nd, you know, Mother Nature has been developing that product for a very long time. And one of the things that we see within natural psilocybin containing fungi is there’s other compounds that potentially have therapeutic benefit that exist with fungi – well known compounds like melatonin, serotonin, and cysteine, all the way to previously undiscovered compounds, potentially, that have therapeutic benefit,” added Nyquvest.
Numinus is aiming to use the clinical trials to establish how effectively MDMA can be used to treat post-traumatic stress disorder (PTSD). The company says it’s ready to begin production of MDMA for treatment of PTSD.
“I feel like I’m probably a broken record on here talking about the maps results but just to reiterate, their Phase Three, over 80% of participants saw significant clinical reduction in their symptoms with MDMA for treatment resistant post-traumatic stress disorder, and 67% no longer met the PTSD criteria. So essentially a cure for PTSD, and again, with people with treatment-resistant PTSD,” added the CEO.